09:06 AM EDT, 03/11/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) reported a Q4 net loss Monday of $0.86 per diluted share, narrowing from a loss of $8.86 a year earlier.

Three analysts polled by Capital IQ expected a loss of $0.71.

The clinical-stage company reported no revenue for the quarter ended Dec. 31, matching the average estimate of four analysts polled by Capital IQ.

The company said it ended Q4 with $121.5 million in cash, cash equivalents, and investments, sufficient to fund operations into 2027.

Lexeo shares were up more than 7% in recent Monday premarket activity.

Price: 16.24, Change: +1.11, Percent Change: +7.34